AU2019362879B2 - Compositions and methods for immunotherapy - Google Patents

Compositions and methods for immunotherapy

Info

Publication number
AU2019362879B2
AU2019362879B2 AU2019362879A AU2019362879A AU2019362879B2 AU 2019362879 B2 AU2019362879 B2 AU 2019362879B2 AU 2019362879 A AU2019362879 A AU 2019362879A AU 2019362879 A AU2019362879 A AU 2019362879A AU 2019362879 B2 AU2019362879 B2 AU 2019362879B2
Authority
AU
Australia
Prior art keywords
seq
sequence
nos
rna
guide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019362879A
Other languages
English (en)
Other versions
AU2019362879A1 (en
Inventor
Amy Melissa BECKER
Surbhi GOEL
Sarah HESSE
Troy Aaron LUSTER
Birgit Schultes
Pooja VINAY
Stephanie A. YAZINSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intellia Therapeutics Inc
Original Assignee
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellia Therapeutics Inc filed Critical Intellia Therapeutics Inc
Publication of AU2019362879A1 publication Critical patent/AU2019362879A1/en
Application granted granted Critical
Publication of AU2019362879B2 publication Critical patent/AU2019362879B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019362879A 2018-10-16 2019-10-15 Compositions and methods for immunotherapy Active AU2019362879B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862746522P 2018-10-16 2018-10-16
US62/746,522 2018-10-16
US201862747037P 2018-10-17 2018-10-17
US62/747,037 2018-10-17
PCT/US2019/056399 WO2020081613A1 (en) 2018-10-16 2019-10-15 Compositions and methods for immunotherapy

Publications (2)

Publication Number Publication Date
AU2019362879A1 AU2019362879A1 (en) 2021-05-27
AU2019362879B2 true AU2019362879B2 (en) 2026-02-19

Family

ID=68502008

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019362879A Active AU2019362879B2 (en) 2018-10-16 2019-10-15 Compositions and methods for immunotherapy

Country Status (15)

Country Link
US (1) US20210340530A1 (https=)
EP (1) EP3867379A1 (https=)
JP (2) JP2022512703A (https=)
KR (1) KR20210091160A (https=)
CN (1) CN113227374A (https=)
AU (1) AU2019362879B2 (https=)
BR (1) BR112021007025A2 (https=)
CA (1) CA3116132A1 (https=)
CO (1) CO2021006301A2 (https=)
IL (1) IL282225A (https=)
MX (1) MX2021004214A (https=)
PH (1) PH12021550849A1 (https=)
SG (1) SG11202103571XA (https=)
TW (1) TW202035693A (https=)
WO (1) WO2020081613A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226363A1 (en) * 2020-05-08 2021-11-11 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
MX2023004822A (es) * 2020-10-26 2023-05-10 Arsenal Biosciences Inc Loci de puerto seguro.
US20240026351A1 (en) * 2020-10-30 2024-01-25 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting trac and uses thereof
MX2023006878A (es) 2020-12-11 2023-07-31 Intellia Therapeutics Inc Composiciones y métodos para reducir el mhc de clase ii en una célula.
CR20230320A (es) 2020-12-23 2023-10-23 Intellia Therapeutics Inc Composiciones y métodos para reducir los hla-a en una célula
WO2022140587A1 (en) 2020-12-23 2022-06-30 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying ciita in a cell
CN116848235A (zh) 2020-12-30 2023-10-03 因特利亚治疗公司 工程化t细胞
EP4288525A1 (en) 2021-02-08 2023-12-13 Intellia Therapeutics, Inc. Natural killer cell receptor 2b4 compositions and methods for immunotherapy
EP4288089A2 (en) 2021-02-08 2023-12-13 Intellia Therapeutics, Inc. T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
CN117042793A (zh) 2021-02-08 2023-11-10 因特利亚治疗公司 用于免疫疗法的淋巴细胞活化基因3(lag3)组合物和方法
CN117083292A (zh) * 2021-04-02 2023-11-17 科济生物医药（上海）有限公司 Cs1工程化细胞及其组合物
JP2024534114A (ja) 2021-08-24 2024-09-18 インテリア セラピューティクス，インコーポレイテッド 細胞療法用のプログラム細胞死タンパク質１（ｐｄ１）組成物及び方法
AU2022335499A1 (en) 2021-08-27 2024-02-22 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
JP2024540723A (ja) 2021-11-03 2024-11-01 インテリア セラピューティクス，インコーポレーテッド 免疫療法のためのｃｄ３８組成物及び方法
AU2022396533A1 (en) 2021-11-24 2024-05-02 Metagenomi Therapeutics, Inc. Endonuclease systems
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
EP4511397A1 (en) 2022-04-19 2025-02-26 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
WO2023225670A2 (en) * 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
AU2023293131A1 (en) 2022-06-16 2024-12-12 Intellia Therapeutics, Inc. Compositions and methods for reducing mhc class i in a cell
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells
WO2024088401A1 (en) * 2022-10-28 2024-05-02 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for reducing immunogenicity and graft versus host response
WO2024186971A1 (en) 2023-03-07 2024-09-12 Intellia Therapeutics, Inc. Cish compositions and methods for immunotherapy
IL326191A (en) 2023-08-14 2026-03-01 Intellia Therapeutics Inc Compositions and methods for genetic modification of transforming growth factor beta receptor type 2 (tgfβr2)
WO2025038642A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying cd70
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
WO2025038646A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Cd70 car-t compositions and methods for cell-based therapy
WO2025049631A1 (en) * 2023-08-28 2025-03-06 Kyverna Therapeutics, Inc. Allogeneic car-t cell therapies and manufacture thereof
WO2025077790A1 (en) * 2023-10-11 2025-04-17 Chengdu Ucello Biotechnology Co., Limited Engineered immune cells and uses thereof
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025137439A2 (en) 2023-12-20 2025-06-26 Intellia Therapeutics, Inc. Engineered t cells
WO2025255308A1 (en) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
JP3131222B2 (ja) 1991-12-24 2001-01-31 アイシス・ファーマシューティカルス・インコーポレーテッド ギャップを有する２′修飾オリゴヌクレオチド
JPH10500310A (ja) 1994-05-19 1998-01-13 ダコ アクティーゼルスカブ 淋菌及びトラコーマ クラミジアの検出のためのｐｎａ プローブ
WO2014093655A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
DK2931891T3 (da) 2012-12-17 2019-08-19 Harvard College Rna-styret modificering af menneskelige genomer
CN107879960B (zh) 2013-03-08 2021-06-22 诺华股份有限公司 用于传递活性成分的脂质和脂质组合物
US9937207B2 (en) * 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
WO2014191128A1 (en) * 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
WO2015161276A2 (en) * 2014-04-18 2015-10-22 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20150376586A1 (en) 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
KR20230156800A (ko) 2015-03-03 2023-11-14 더 제너럴 하스피탈 코포레이션 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제
EP3274454B1 (en) * 2015-03-25 2021-08-25 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
AU2016243583B2 (en) * 2015-03-27 2022-03-10 President And Fellows Of Harvard College Modified T cells and methods of making and using the same
EP3277294B1 (en) * 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
EP3389677B1 (en) * 2015-12-18 2024-06-26 Sangamo Therapeutics, Inc. Targeted disruption of the t cell receptor
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
EP3423580A1 (en) * 2016-03-04 2019-01-09 Editas Medicine, Inc. Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
LT3436077T (lt) 2016-03-30 2025-06-25 Intellia Therapeutics, Inc. Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams
CN106191062B (zh) * 2016-07-18 2019-06-14 广东华南疫苗股份有限公司 一种tcr-/pd-1-双阴性t细胞及其构建方法
SG10202106058WA (en) 2016-12-08 2021-07-29 Intellia Therapeutics Inc Modified guide rnas
WO2018132479A1 (en) * 2017-01-10 2018-07-19 The General Hospital Corporation Modified t cells and methods of their use
WO2018191490A1 (en) * 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
MX2019013514A (es) * 2017-05-12 2020-01-20 Crispr Therapeutics Ag Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
EP3686275A4 (en) * 2017-09-18 2021-09-29 Edigene Inc. GENE EDITING LYMPHOCYTE T AND RELATED USE
JP2020537515A (ja) * 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
SG11202004026QA (en) * 2017-10-30 2020-05-28 Pact Pharma Inc Primary cell gene editing
CN109750035B (zh) * 2017-11-02 2020-06-05 上海邦耀生物科技有限公司 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
CN107746831B (zh) * 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法
CN107828730B (zh) * 2017-11-07 2019-04-30 南京北恒生物科技有限公司 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法
MA52207A (fr) * 2018-04-05 2021-02-17 Editas Medicine Inc Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés
CA3094468A1 (en) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MX2020011254A (es) * 2018-04-27 2020-11-12 Crispr Therapeutics Ag Celulas t car anti-bcma para agotamiento de celulas de plasma.
CN112752767A (zh) * 2018-04-27 2021-05-04 克里斯珀医疗股份公司 细胞毒性t细胞耗竭的方法和组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069282A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Altering gene expression in modified t cells and uses thereof

Also Published As

Publication number Publication date
MX2021004214A (es) 2021-07-15
AU2019362879A1 (en) 2021-05-27
BR112021007025A2 (pt) 2021-08-03
IL282225A (en) 2021-05-31
KR20210091160A (ko) 2021-07-21
TW202035693A (zh) 2020-10-01
CA3116132A1 (en) 2020-04-23
CO2021006301A2 (es) 2021-06-10
US20210340530A1 (en) 2021-11-04
PH12021550849A1 (en) 2021-12-06
WO2020081613A1 (en) 2020-04-23
EP3867379A1 (en) 2021-08-25
SG11202103571XA (en) 2021-05-28
CN113227374A (zh) 2021-08-06
JP2022512703A (ja) 2022-02-07
JP2025138662A (ja) 2025-09-25

Similar Documents

Publication Publication Date Title
AU2019362879B2 (en) Compositions and methods for immunotherapy
AU2021396403A1 (en) Compositions and methods for reducing mhc class ii in a cell
AU2021410751A1 (en) Compositions and methods for genetically modifying ciita in a cell
US20230374456A1 (en) T-Cell Immunoglobulin and Mucin Domain 3 (TIM3) Compositions and Methods for Immunotherapy
US20230383252A1 (en) Natural Killer Cell Receptor 2B4 Compositions and Methods for Immunotherapy
US20230383253A1 (en) Lymphocyte Activation Gene 3 (LAG3) Compositions and Methods for Immunotherapy
KR20250068591A (ko) B2m 발현의 후성적 조절을 위한 조성물 및 방법
AU2023293131A1 (en) Compositions and methods for reducing mhc class i in a cell
US20240228577A1 (en) Programmed Cell Death Protein 1 (PD1) Compositions and Methods for Cell-Based Therapy
HK40058210A (en) Compositions and methods for immunotherapy
HK40096021A (zh) 用於免疫疗法的淋巴细胞活化基因3(lag3)组合物和方法
HK40109563A (zh) 用於基於细胞的疗法的程序性细胞死亡蛋白1(pd1)组合物和方法
WO2025038642A1 (en) Compositions and methods for genetically modifying cd70
HK40096263A (zh) 用於免疫疗法的t细胞免疫球蛋白和粘蛋白结构域3(tim3)组合物和方法
CN116802274A (zh) 用于减少细胞中ii类mhc的组合物和方法
HK40103611A (zh) 用於免疫疗法的自然杀伤细胞受体2b4组合物和方法